Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-HER3/topoisomerase I inhibitor antibody-drug conjugate IBI133

An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against human epidermal growth factor receptor 3 (HER3; ErbB3) conjugated to a topoisomerase I (TopoI) inhibitor-based payload, with potential antineoplastic activity. Upon administration of anti-HER3/TopoI inhibitor ADC IBI133, the anti-HER3 antibody moiety targets and binds to HER3 expressed on tumor cells. Upon cellular uptake, the TopoI inhibitor inhibits DNA topoI activity, thereby inhibiting DNA replication which results in cell cycle arrest and tumor cell apoptosis. This inhibits the proliferation of HER3-expressing tumor cells. HER3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in tumors.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-HER3 ADC IBI133
anti-HER3 antibody-drug conjugate IBI133
anti-HER3/TopIi antibody-drug conjugate IBI133
anti-HER3/TopoI inhibitor ADC IBI133
IBI 133
IBI-133
IBI133
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search